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Abstract
Background: The Ehlers-Danlos Syndrome (EDS) is a heritable connective tissue disorder characterized by hyperextensible
skin, joint hypermobility and soft tissue fragility. The classic subtype of EDS is caused by mutations in one of the type V
collagen genes (COL5A1 and COL5A2). Most mutations affect the type V collagen helical domain and lead to a diminished or
structurally abnormal type V collagen protein. Remarkably, only two mutations were reported to affect the extended, highly
conserved N-propeptide domain, which plays an important role in the regulation of the heterotypic collagen fibril diameter.
We identified a novel COL5A1 N-propeptide mutation, resulting in an unusual but severe classic EDS phenotype and a
remarkable splicing outcome.
Methodology/Principal Findings: We identified a novel COL5A1 N-propeptide acceptor-splice site mutation (IVS6-2A.G,
NM_000093.3_c.925-2A.G) in a patient with cutaneous features of EDS, severe progressive scoliosis and eye involvement.
Two mutant transcripts were identified, one with an exon 7 skip and one in which exon 7 and the upstream exon 6 are
deleted. Both transcripts are expressed and secreted into the extracellular matrix, where they can participate in and perturb
collagen fibrillogenesis, as illustrated by the presence of dermal collagen cauliflowers. Determination of the order of intron
removal and computational analysis showed that simultaneous skipping of exons 6 and 7 is due to the combined effect of
delayed splicing of intron 7, altered pre-mRNA secondary structure, low splice site strength and possibly disturbed binding
of splicing factors.
Conclusions/Significance: We report a novel COL5A1 N-propeptide acceptor-splice site mutation in intron 6, which not only
affects splicing of the adjacent exon 7, but also causes a splicing error of the upstream exon 6. Our findings add further
insights into the COL5A1 splicing order and show for the first time that a single COL5A1 acceptor-splice site mutation can
perturb splicing of the upstream exon.
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Introduction
Type V collagen, a quantitatively minor fibrillar collagen that is
widely distributed among connective tissues, plays an important
role in the organization of heterotypic type I/V collagen fibrils [1].
Its major isoform is the [a1(V)]2a2(V) heterotrimer, composed of
two proa1-chains and one proa2-chain [1,2]. The ability of type V
collagen to regulate the collagen fibril diameter has been
attributed to its amino(N)-propeptide [1]. The a1(V)-N-propeptide
is a multidomain region, composed of an N-terminal TSPN-1
(thrombospondin-1 N-terminal domain like) domain, a variable
(VAR) domain, a small interrupted collagenous domain (COL2)
and a non-collagenous (NC2) domain (Figure 1A), whereas the
a2(V)-N-propeptide consists of only one cysteine-rich (CR)
domain. In vivo, type V procollagen processing by Bone
Morphogenetic Protein-1 (BMP-1) releases the TSPN-1 domain
from the proa1(V)-chain and removes the carboxyl(C)-propeptide
from the proa2(V)-chain. Apparently, the a2(V)-N-propeptide is
not processed by any protease, while the proa1(V)-C-propeptide is
cleaved by furin. As such, the mature a1(V)-chain retains the
VAR, COL2 and NC2 domains and the mature a2(V)-chain
retains the CR domain at its N-terminus [3]. These domains are
thought to regulate the diameter of heterotypic type I/V collagen
fibrils [1].
Defects in the proa1(V)- or the proa2(V)-chain, encoded by
COL5A1 and COL5A2 respectively, lead to classic Ehlers-Danlos
Syndrome (EDS), formerly known as EDS type I, ‘‘gravis’’
(MIM# 130000) and EDS type II, ‘‘mitis’’ (MIM# 130010). This
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bility of the skin, delayed wound healing, atrophic scarring and
generalized joint hypermobility. Typically, large composite
collagen fibrils are observed in the dermis of classic EDS patients
(collagen ‘‘cauliflowers’’) [4]. The majority of COL5A1 mutations
introduce a premature stopcodon, resulting in nonsense-mediated
mRNA decay and decreased type V (pro)collagen production
[5,6]. A minority of mutations causes the production of
structurally abnormal type V collagen, the secretion of which
may be impaired but not completely abolished [5,6,7]. We
previously reported two other types of defects in type V collagen
that prevent incorporation of the mutant a-chain into the
[a1(V)]2a2(V) heterotrimer, respectively deletion of one or more
cysteine residues in the a1(V)-C-propeptide and signal peptide
mutations that impair secretion of the mutant a1(V)-chain
[7,8,9]. So far only two mutations resulting in EDS have been
described within the highly conserved a1(V)-N-propeptide
(Figure 1A) [10,11]. The first mutation, p.Gly530Ser, is located
in the COL2 domain and is thought to be disease-causing when
present in homozygous state, and disease-modifying when
occurring in heterozygous state [10]. The second mutation,
IVS4-2A.G, is an acceptor-splice site mutation and results in
several in-frame splice transcripts [11]. In the two major splice
forms, the BMP-1 cleavage site of the a1(V)-N-propeptide is
deleted, which results in the retention of the TSPN-1 domain
[11].
In the current study, we report a novel COL5A1 acceptor-splice
site mutation in intron 6 (IVS6-2A.G, NM_000093.3_c.925-
2A.G) that affects splicing of exon 7 and the upstream exon
6 and causes an EDS phenotype, characterized by mild
cutaneous involvement, eye involvement and severe progressive
kyphoscoliosis.
Results
Clinical findings
The patient is the only child of healthy non-consanguineous
parents (Figure 1A). She was born at 31-weeks of gestation after an
uneventful pregnancy and premature rupture of the membranes.
Her birth length was 46 cm, birth weight was 2050 g and head
circumference was 38 cm at two months of age. She presented
marked joint hyperlaxity. Neuromotor development was normal,
although she gave a clumsy impression. At the age of 6 years she
sustained a supracondylar humerus fracture after a fall. Her skin
was fragile, with delayed wound healing and easy bruising. In
addition to amblyopia and hypermetropia, she had converging
strabism for which she was operated twice. She suffered from
retinal detachment in the right eye. At age 9 years, she developed a
severe, rapidly progressing kyphoscoliosis (Figure 2A–C).
Clinical examination at the age of 12 years and 4 months
showed a girl with a length of 141.3 cm (P3), weight of 44 kg (P50)
and head circumference of 51.6 cm (P50). Inspection of the facial
features revealed prominent ears, light-blue sclerae, bilateral
epicanthic folds, mild micrognathia and dental crowding
(Figure 1A). She had very soft, velvety and hyperextensible skin,
with multiple ecchymoses and hemosiderine deposits on the lower
limbs (Figure 1B). Scarring was minimal with only one small
atrophic scar on the left elbow. Small molluscoid pseudotumors
were present on the side of her feet. She presented generalized
joint hypermobility with a Beighton score of 7/9, marked
kyphoscoliosis, mild pectus excavatum and broad, flat feet.
At age 13
1/2 years her main problems included fatigue, muscle
weakness with reduced physical capacity and rapidly progressive
kyphoscoliosis, for which she had corrective surgery (Figure 2A–
D). Clinical evaluation four months after surgery showed that the
Figure 1. Clinical pictures of the patient. A–B. The patient at age of 12 yrs 4 months, presenting marked scoliosis, mild pectus excavatum and
broad, flat feet. Scarring is only minimal but she presents hemosiderine deposits on the lower limbs.
doi:10.1371/journal.pone.0020121.g001
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normal.
Biochemical and Ultrastructural Collagen Studies
SDS-PAGE analysis of procollagens and pepsin-digested
collagens from the cell layer and medium fraction showed a
normal electrophoretic pattern for types I and III (pro)collagen.
Unfortunately, no definite conclusion could be drawn for type V
collagen as the bands representing the a1(V)- and a2(V)-chains
were too low in intensity (data not shown). This finding is in
agreement with a previous report demonstrating that biochemical
analysis is a poor diagnostic test for detecting type V collagen
abnormalities [5]. Ultrastructural studies revealed collagen
bundles with fibrils of variable diameter and irregular interfibrillar
spaces enriched in granulo-filamentous deposits (Figure 3A). We
observed numerous cauliflower-like collagen fibrils, a hallmark of
disturbed collagen fibrillogenesis, typically found in the dermis of
classic EDS patients (Figure 3A). While most elastic fibers
presented normal ultrastructural features, in some osmiophilic
elements were increased (Figure 3B). In addition, the dermal
fibroblasts of the patient exhibited a dilated endoplasmic reticulum
(data not shown).
Molecular analysis
In view of the rapidly progressing kyphoscoliosis and ocular
symptoms, mutation screening of PLOD1 was initially per-
formed to exclude the kyphoscoliotic type of EDS (EDS, type
VIA), but no PLOD1 mutation was identified. Considering her
fragile skin with delayed wound healing, further molecular studies
were directed towards the type V collagen genes. A COL5A1 null-
allele test showed that both COL5A1 alleles were expressed,
thereby excluding the presence of a COL5A1 null-allele. COL5A1
mutation screening identified a heterozygous A-to-G transi-
tion in the acceptor-splice site of exon 7 (IVS6-2A.G,
NM_000093.3_c.925-2A.G) (Figure 4A–C), which was absent
in the unaffected mother. Unfortunately, gDNA of the patients’
unaffected father was unavailable. Mutation screening of COL5A2
was normal.
The NM_000093.3_c.925-2A.G substitution abolished the
COL5A1 exon 7 acceptor-splice site, as predicted by the Splice Site
Prediction by Neural Network software. HSF analysis confirmed
disruption of the acceptor-splice site and predicted that the
potential branch point of intron 6 would be broken. In addition,
the HSF software predicted that the NM_000093.3_c.925-2A.G
mutation can interfere with binding of several SR proteins, such as
SC35, SRp40 and SF2/ASF, to SREs, which may cause
malpositioning of the spliceosome.
The ExonScan software was used to predict potential exons in
the entire COL5A1-N-propeptide encoding region (spanning exons
1 to 14). Interestingly, while exons 2, 3, 4, 8, 9, 10, 11 and 13 were
correctly predicted, exons 1, 5, 6, 7, 12 and 14 were not
recognized. The fact that, despite their weak splice sites, these
exons are recognized in vivo by the spliceosome suggests that other
sequences or pre-mRNA secondary structures are involved in
directing the spliceosome to these exons. Subsequently, the Mfold
program was used to determine local pre-mRNA secondary
structures surrounding the exon 7 acceptor-splice site. We
evaluated an 80-mer containing the exon 7 acceptor-splice site
and neighboring sequences. In the wild type allele, the exon 7
acceptor-splice site was present in a ‘‘loop’’ structure and thus
easily accessible for the splicing machinery (Supplementary Figure
S1). In contrast, in the presence of the NM_000093.3_c.925-
2A.G mutation, the pre-mRNA secondary structures changed
and the acceptor-splice site shifted towards a ‘‘stem’’ structure,
making this site less accessible for the spliceosome (Supplementary
Figure S1).
To investigate whether the NM_000093.3_c.925-2A.G muta-
tion gave rise to different COL5A1 mRNA transcripts, we cloned
Figure 2. X-ray photographs of the thorax of the patient. A. Severe scoliosis. B. Close-up of the thoracic scoliosis. C. X-ray side view showing
the kyphosis of the patient. D. X-ray of the thorax of the patient after corrective surgery for the progressive scoliosis.
doi:10.1371/journal.pone.0020121.g002
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different mutant mRNA transcripts were detected, which were
present in equal amounts: one transcript lacked exon 7, the second
transcript missed exon 7 and the upstream exon 6 (Figure 4A–B).
Deletion of exon 7 and of exons 6 and 7 removed 80 and 126
amino acids respectively from the VAR domain.
Figure 3. Ultrastructural electron microscopy studies. A. In addition to the high variability in diameter of the collagen fibrils, cauliflower-like
collagen fibrils (arrows) and granulo-filamentous deposits (*) in the interfibrillar spaces are seen. B. Elastic fiber with increased osmiophilic elements in
the elastin matrix (*).
doi:10.1371/journal.pone.0020121.g003
Figure 4. NM_000093.3_c.925-2A.G (IVS6-2A.G) mutation data. A. Exon and domain structure of the COL5A1 N-propeptide encoding
region. Known mutations and the NM_000093.3_c.925-2A.G (IVS6-2A.G) mutation are indicated. Deletion of exon 7 and deletion of exon 6 and 7
affect the VAR domain of the pro-a1(V)-N-propeptide. B. RT-PCR was performed using primers located in exon 4 (828F) and exon 8 (1427R). Three
different products are present in the patient sample (P). The upper band corresponds to the wild type product, the middle band corresponds to the
product in which exon 7 is deleted, and the lower band corresponds to the product in which both exon 6 and exon 7 are deleted. These bands were
cloned and sequenced. In the control sample (C) only the wild type product is detected. C. Electropherogram of the NM_000093.3_c.925-2A.G (IVS6-
2A.G) mutation. D. Western blot analysis of HEK293-T transfected with WT, exon7deletion-pNa1(V)-pCEP4 and exon6_exon7deletion-pNa1(V)-pCEP4
constructs respectively. All three constructs are translated (Cell) and efficiently secreted into the extracellular matrix (Medium).
doi:10.1371/journal.pone.0020121.g004
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pNa1(V)
Next, we investigated whether both mutant transcripts were
translated and secreted into the extracellular matrix. The wild type
expression plasmid encoded the entire a1(V)-N-propeptide
domain (pNa1(V)-pCEP4) [12], while the first mutant expression
construct lacked exon 7 (exon7deletion-pNa1(V)-pCEP4) and the
second lacked exons 6 and 7 (exon6_exon7deletion-pNa1(V)-
pCEP4). Immunoblotting experiments on the cell and medium
fraction of transfected HEK293-T cells demonstrated that,
analogous to the wild type protein, both aberrant proteins were
produced and efficiently secreted into the extracellular matrix
(Figure 4D). As such, these mutant a1(V)-chains are thought to be
incorporated into type V collagen heterotrimers and to disturb
normal type I/V collagen fibrillogenesis, as illustrated by the
presence of collagen cauliflowers observed in the patients’ dermis.
Determination of Intron Removal
To determine the order of intron removal in the region between
exons 5 and 9, paired intron/exon primers were used on nuclear
pre-mRNA splicing intermediates. When an exon 5/intron 7
primer pair was used (Figure 5A), a PCR product remained
present for 60 min in the patient and control cells. This PCR
fragment corresponded to the mRNA product in which both
intron 5 and 6 had been removed, but in which intron 7 was still
present. We concluded that intron 7 is removed more slowly from
the mRNA than intron 5 and intron 6.
When using an exon 6/intron 8 primer pair (Figure 5B), a PCR
band, in which intron 6 and 7 are removed, was visible in the
control sample as a gradient line which decreases in time.
However, this band was not observed in the patient sample. We
concluded that, while in the control sample intron 8 is removed
from the pre-mRNA in a time-dependent manner, in the patient
sample removal of intron 8 is accelerated and removal of intron 6
and/or 7 is delayed. Similar results were obtained with the primer
pair exon 5/intron 8 (data not shown).
Additional studies with primers in exon 6 and intron 7
(Figure 5C) showed a persistent PCR signal in both samples,
consistent with the slow removal of intron 7. This suggests that
intron 6 is removed prior to intron 7.
Primers located in intron 6 and exon 8 (Figure 5D) yielded a
PCR product in which intron 7 is removed. In the control sample
only a low intensity PCR signal was visible. But, in the patient
sample a persistent PCR signal with higher intensity was detected,
indicating that pre-mRNA splicing intermediates, still containing
intron 6, accumulate. As such, the splice acceptor-mutation causes
delayed splicing of intron 6. In addition, primers located in intron
7 and exon 9 (Figure 5E) demonstrated the slow removal of intron
7 in both the control and the patient sample, again confirming that
intron 7 is a slowly removed intron. A more intense PCR signal
was observed after 40 and 60 minutes in the patient sample when
compared to control, indicating that in the presence of the
NM_000093.3_c.925-2A.G mutation splicing of intron 7 is even
more delayed (Figure 5E). This implies that the
NM_000093.3_c.925-2A.G mutation might not only disturbs
splicing of the affected intron 6, but also further delays splicing of
the already slowly spliced-out intron 7.
These data are consistent with a model implicating at least two
pathways of intron removal between exons 5 and 9 in the presence
of the NM_000093.3_c.925-2A.G mutation (Figure 5F). Our
results indicate that the first splicing event is removal of intron 8.
Subsequently, at least two orders of splicing are possible. In the
first pathway (left side of figure 5F), the acceptor-splice site of exon
6, although predicted to be weak (strength 0.19), is recognized
leading to removal of intron 5, thereby generating an mRNA
splicing intermediate with a fused exon 5/exon 6 and in which
exon 7 is flanked by intron 6 and 7. Due to the presence of the
NM_000093.3_c.925-2A.G mutation, the acceptor-splice site of
exon 7 is abolished, resulting in skipping of exon 7.
In the second pathway (right side of figure 5F), the spliceosome
does not recognize the acceptor-splice site of exon 6, possibly due
to changes in the secondary structure of the pre-mRNA induced
by the mutation. Neither does it recognize the mutated acceptor-
splice site of exon 7. Therefore the spliceosome uses the donor-
splice site of exon 5 and the acceptor-splice site of exon 8. This
causes the generation of the two-exon-skip transcript, lacking both
exon 6 and 7.
The complexity of intron removal in the N-propeptide encoding
region of the COL5A1 gene is further underscored by the study of
Takahara et al., 2002 [11], which showed the presence of several
pathways of intron removal, resulting in a complex splicing
outcome of the IVS4-2A.G mutation. Furthermore, we and
others [11] used only part of the sequence of the entire COL5A1
gene, thereby possibly excluding other regions present in COL5A1
which may contribute to the observed splicing pattern. Combining
the findings presented here with previous results suggest that other
pathways of intron removal may exist. This may be supported by
the fact that we were unable to detect the higher molecular weight
PCR bands, corresponding to nuclear mRNA in which all introns
remain present.
Discussion
Most reported type V collagen defects cause the generation of a
non-functional COL5A1 allele, while only a minority lead to
structurally abnormal type V collagen (i.e. glycine substitutions
and splicing errors in the collagen triple helix, C-propeptide
mutations). Interestingly, most of the currently identified type V
collagen defects seem to act in a similar way, causing ‘‘functional’’
haploinsufficiency of type V collagen [7]. We present here a novel
COL5A1 acceptor-splice site mutation which is located in the N-
propeptide domain, a region playing a significant role in the
regulation of collagen fibril diameter [1]. We show that this
mutation results in the generation of two mutant transcripts which
are each predicted to generate a truncated protein. Even though
we did not detect these truncated type V collagen proteins with
routine biochemical SDS-PAGE analysis, the production and
secretion of both truncated proteins in our recombinant expression
system and the presence of collagen cauliflowers in the patients’
dermis (Figure 3A), a hallmark of disturbed collagen fibrillogenesis,
suggest that these truncated proteins are indeed produced and
secreted into the extracellular matrix where they interfere with
collagen fibrillogenesis. Although the N-propeptide domain is very
highly conserved, this mutation is only the third mutation reported
in this domain [10,11]. Furthermore, our detailed study of the
splicing outcome of this acceptor-splice site mutation adds to the
growing number of studies investigating complex splicing
outcomes and determining additional factors needed for correct
pre-mRNA splicing. In contrast to other type V collagen
mutations, the associated phenotype is not typical for classic
EDS but differs from it in the mild cutaneous involvement, rapidly
progressive, severe kyphoscoliosis (Figure 1A–D) and ocular
complications. In view of the latter, molecular analysis of the
PLOD1 gene was performed, which excluded its contribution to
the phenotype.
As demonstrated by numerous studies, several factors determine
the fidelity of pre-mRNA splicing; e.g. four intronic core splicing
signals (donor-splice site, acceptor-splice site, polypyrimidine tract
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(cDNA). Nuclear RNA was isolated from cultured fibroblasts after incubation with Actinomycine D (ActD) for 0, 5, 10, 20, 40 and 60 min to stop
transcription. A. For both the patient and the control sample a persistent PCR product was observed, implying that intron 7 is slowly removed. B. The
exon6/intron 8 primer pair resulted in a gradually decreasing PCR band in the control sample. This band is not visible in the patient. We conclude that
intron 8 is removed quickly in both the control and the patient sample; but intron 8 is removed more quickly in the patient sample when compared
to the control sample. C. PCR with primers in exon 6 and intron 7 showed a persistent PCR band for both control and patient sample, suggesting that
intron 6 is removed prior to intron 7. D. The intron6/exon8 primer pair resulted in a distinctly visible band for the patient sample, while for the control
sample only a very weak PCR signal was obtained. This suggests that the NM_000093.3_c.925-2A.G mutation causes delayed splicing of intron 6.
E. Intron 7/exon9 primers showed a weak persistent PCR band in both control and patient sample. Moreover, in the patient sample, an accumulation
in time was seen. As such, it appears that the NM_000093.3_c.925-2A.G mutation also delays splicing of intron 7. F. Predicted pathways of intron
removal in the mutant COL5A1 allele (x indicates the location of the NM_000093.3_c.925-2A.G mutation). Intron 8 is quickly removed. Subsequently,
two pathways are possible. In the first pathway, intron 5 is removed, leading to a fused exon5/exon 6. The next step is skipping of exon 7 (left side of
the panel). In the second pathway (right side of the panel), the weak acceptor-splice site of exon 6 is not used by the spliceosome. Instead, the
combined use of the donor-splice site of exon 5 with the acceptor-splice site of exon 8 leads to skipping of both exons 6 and 7. Green, acceptor-splice
site; blue, donor-splice site; red, mutated exon 7 acceptor-splice site.
doi:10.1371/journal.pone.0020121.g005
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acting factors and additional characteristics such as splice site
strength, intron/exon architecture, pre-mRNA secondary struc-
ture, extracellular signaling and the transcription process itself (e.g.
the C-terminal domain of RNA polymerase II is required for
efficient pre-mRNA processing) [13,14,15,16,17]. While the
majority of the hitherto characterized pre-mRNA splicing defects,
involved in heritable disorders, reside in the donor- and acceptor-
splice sites, recent studies have documented several mutations with
a very complex splicing outcome [11,18,19,20,21,22]. Our study
expands this latter group of mutations. The novel COL5A1
acceptor-splice site mutation, NM_000093.3_c.925-2A.G (IVS6-
2A.G) generates two mutant transcripts, one with an exon 7 skip
and one with a two-exon-skip of exon 7 and the upstream exon 6
(Figure 4A–B). Several computational calculations predicted that
the IVS6-2A.G mutation interferes with the normal splicing
process and leads to a profound change in pre-mRNA secondary
structure surrounding the exon 7 acceptor-splice site (Supplemen-
tary Figure S1). Interestingly, a previously reported COL5A1-
acceptor-splice site mutation (IVS4-2A.G) does not only affect
the splicing of exon 5, but also of the downstream exon 6 [11], and
also generates two minor transcripts by using a cryptic splice site in
exon 5. The splicing outcome of the IVS4-2A.G mutation is of
particular interest in relation to our results. More specifically, none
of these three ‘‘affected’’ exons (exon 5–6–7) were predicted as
possible exons by the ExonScan software, an algorithm based on
splice site strength and the presence of splicing regulatory
elements. This implies that additional factors are needed for the
correct guidance of the spliceosome to these three exons, a
hypothesis that is further supported by the findings published by
Takahara et al., 2002 [11]. However, conversely, the previous
study [11] suggested that, when splice site mutations lead to the
generation of a two-exon-skip, the exons chosen to be skipped
would differ depending on whether the mutation is at an acceptor-
splice site or a donor-splice site. This would mean that an
acceptor-splice site mutation leads to removal of the two
downstream exons, while a donor-splice site mutation would
allow skipping of the two exons upstream from the mutation site.
However, as the mutation described here affects an acceptor-splice
site and leads to skipping of the upstream exon in the two-exon-
skip outcome, these findings illustrate that the exons involved in
the two-exon-skip splicing outcome do not solely depend on
whether the mutation affects an acceptor- or donor-splice site.
Interestingly, although the IVS6-2A.G mutation, presented here,
and the IVS4-2A.G mutation [11] are located very closely to
each other, it is unclear why these patients differ in clinical
phenotype. While our patient has rather atypical findings of classic
EDS, the patient described by Takahara et al., 2002 [11]
presented with typical signs of classic EDS (type I, gravis type)
such as very soft, hyperextensible skin, many scars on his forehead
and shins, and generalized small and large joint hypermobility.
We also analyzed the mechanism whereby the present mutation
caused the generation of two different mutant transcripts in more
detail by determining the order of intron removal. Interestingly,
our studies showed that the mutation did not only abolish splicing
of intron 6, but also delayed the removal of intron 7. When
comparing the patient with the control, an intranuclear accumu-
lation in time was observed for the pre-mRNA fragment in which
intron 7 was retained. While all other introns were removed
appropriately, failure to excise intron 6 and delay in splicing of
intron 7 can explain the occurrence of the exon 7 skip (Figure 5F
left panel). The occurrence of the two-exon-skip cannot solely be
explained by these factors, which suggests that beside the order of
intron removal, also changes in the pre-mRNA secondary
structure hamper the spliceosome in recognizing the already weak
acceptor-splice site of exon 6. These findings add on to the finding
that local pre-mRNA secondary structures may interfere or
modulate splice site recognition [13,17,22] and that weak splice
sites need additional factors for the correct guidance of the
spliceosome [11,23,24,25,26].
Taken together, our results extend the phenotypic spectrum
associated with type V collagen defects and show that mutations in
the type V collagen genes may cause EDS phenotypes that differ
from classic EDS. Furthermore, we show that an acceptor-splice
site mutation can result in different mutant transcripts, including a
two-exon-skip involving an upstream exon. Since the outcome of
splice site mutations is influenced by many factors, investigation of
these mutations at the mRNA level is of critical importance to
unravel the true splicing outcome of a specific mutation.
Materials and Methods
Cell culture, Steady State Collagen Labeling and Electron
Microscopy
Skin biopsies were taken from the probands’ inner aspect of the
upper arm. Fibroblast cell culture, steady state collagen labeling
and transmission electron microscopy were performed as de-
scribed previously [5].
The patient and her mother participated in this study following
written informed consent. This study has been approved by the
Ethics Committee of the Ghent University Hospital, Ghent,
Belgium.
Molecular Analysis
Genomic DNA was extracted (DNeasy; Invitrogen) from the
probands’ skin fibroblasts and from a blood sample of the proband
and her unaffected mother. Total RNA (TRIZOL, Invitrogen) was
extracted from the probands’ skin fibroblasts. For the conversion
to cDNA, MMLV-RTase (Invitrogen) and random hexanucleotide
primers were used [5].
PLOD1 molecular analysis was performed at gDNA level. The
presence of the common duplication of exons 10 to 16
(NG_008159.1_g.25041_33936dup) was excluded by a duplica-
tion-specific PCR as described previously [27]. Subsequently,
exons and flanking intronic sequences were PCR amplified and
sequenced (ABI3730XL, Applied Biosystems).
A COL5A1 null-allele assay and mutation screening of COL5A1
and COL5A2 at gDNA and cDNA level respectively were
performed as described previously [5]. Nucleotide numbering
corresponds to the COL5A1 reference sequence (NM_000093.3)
and is according to HGMD guidelines.
To characterize the mutant mRNA transcripts, the COL5A1
fragment encompassing exons 4 to 8 was PCR amplified (primers
COL5A1-828F - COL5A1-1427R, Table 1) and cloned (TOPO-TA
cloning kit, Invitrogen). Resulting clones were sequenced
(ABI3730XL, Applied Biosystems).
Computational Algorithms and RNA Secondary Structure
Prediction
The effect of the mutation on pre-mRNA splicing was evaluated
using the Splice Site Prediction by Neural Network [28] and the
Human Splicing Finder (HSF) [29] software. The HSF software
also predicts the interaction of several splicing proteins, e.g.
serine/arginine (SR) proteins, with splicing regulatory elements
(SREs). The ExonScan software was used to search the COL5A1
N-propeptide encoding region for candidate exons based on splice
site strength and the presence of SREs [30]. To evaluate local pre-
mRNA folding, COL5A1 80-mers (40 nucleotides from the end of
COL5A1 N-propeptide Missplicing Causes Unusual EDS
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20121intron 6 and 40 nucleotides from the beginning of exon 7) were
folded with the RNA free energy minimization program for
RNAfolding, Mfold version 3.2 [31].
Generation of Mutant COL5A1 N-propeptide-encoding
constructs and Protein Analysis
Starting from the wild type COL5A1 N-propeptide construct
pNa1(V)-pCEP4 [12] (gift from Prof. Ruggiero, IBCP, Lyon,
France), we generated the mutant constructs exon7deletion-
pNa1(V)-pCEP4 and exon6_exon7deletion-pNa1(V)-pCEP4
through in vitro site-directed mutagenesis (QuikChangeH II
Lightning Site-Directed Mutagenesis kit, Stratagene Inc.) using
primers listed in Table 1. The presence of the deletions was
confirmed by sequencing (ABI3730XL, Applied Biosystems).
The expression and secretion of mutant a1(V)-N-propeptide
proteins was evaluated by transfecting the constructs into HEK293-
T cells using Lipofectamine 2000 (Invitrogen). Immunoblotting
experiments were performed as described previously [7].
Determination of Intron Removal
To determine the order of intron removal between COL5A1
exons 5 to 9, we analyzed the splicing intermediates from nuclear
pre-mRNA as reported previously. Briefly, nuclear pre-mRNA
was extracted from cultured control and patient fibroblasts after
incubation with actinomycin D, to stop transcription, for 0, 5, 10,
20, 40, and 60 minutes [11,22]. PCR was performed using
primers listed in Table 1. PCR fragments were analyzed by
agarose gel electrophoresis or by separation on the LabChip GXII
(Caliper LifeSciences) and subsequently sequenced (ABI3730XL,
Applied Biosystems).
Supporting Information
Figure S1 Pre-mRNA secondary structures of 80-mers sur-
rounding the exon 7 acceptor-splice site. Secondary structures
were calculated using Mfold. In the wild type folding, the exon 7
acceptor-splice site is easy accessible for the splicing machinery
due to its presence in a loop structure. In the mutant
NM_000093.3_c.925-2A.G sequence, the exon 7 acceptor-splice
site is shifted towards a ‘‘stem’’ structure, rendering this splice site
difficult to access for the spliceosome. Yellow, last 40 nucleotides of
intron 6; blue, first 40 nucleotides of exon 7; green, wild type exon
7 acceptor-splice site; red, mutant exon 7 acceptor-splice site.
(TIF)
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